FAST FACTS: The Institute for Clinical and Economic Review
Patients, in consultation with their doctors, should make their own medical decisions. But with increasing frequency, an outside organization known as the Institute for Clinical and Economic Review is influencing what treatment options are available for consideration. Today, patients’ access to innovative drugs, life-saving devices and diagnostic testing often rides on this third-party’s value assessment.
WHITE PAPER: The ICER Myth
What stands between patients and the treatment prescribed by their doctors? This paper explores the drawbacks of ICER’s evidence reports and how those issues affect patients.
BLOG: FINAL ICER REPORT LEAVES CYSTIC FIBROSIS COMMUNITY UNEASY
Economists at the Institute for Clinical and Economic Review advise a whopping 77 percent price discount on new CFTR modulators for cystic fibrosis, according to a final evidence report. The drugs can “substantially improve patient health outcomes,” the group concedes, but their prices exceed ICER’s cost-effectiveness threshold. One manufacturer has called ICER’s analysis “a sham.”
So where does this leave patients?
BLOG: ICER REPORT DAMPENS PROSPECTS FOR CYSTIC FIBROSIS TREATMENT
If health plans heed a new report from the Institute for Clinical and Economic Review, patients with few options to treat their cystic fibrosis may soon have fewer still.